正大天晴康方(上海)生物医药科技有限公司(以下简称:正大天晴康方)是由中山康方生物医药有限公司(港交所股票代码:9926.HK)与港股100强的中国生物制药有限公司(港交所股票代码:1177.HK)旗下的正大天晴药业集团股份有限公司合资成立的创新型生物医药公司,致力于肿瘤免疫治疗的抗PD-1单抗药物派安普利(商品名:安尼可;研发代号:AK105)研发、上市销售。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows